Recent studies have suggested that PD‐L1 expression, tumor mutation burden and microsatellite instability status of tumor tissues are potential predictors of the efficacy of anti‐PD1 therapy.6, 7, 8, 9. This evidence concerns the gene CD274 and neoplasm.